The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
(1) Lim SY (2) Shklovskaya E (3) Lee JH (4) Pedersen B (5) Stewart A (6) Ming Z (7) Irvine M (8) Shivalingam B (9) Saw RPM (10) Menzies AM (11) Carlino MS (12) Scolyer RA (13) Long GV (14) Rizos H
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
(1) Amaro A (2) Reggiani F (3) Fenoglio D (4) Gangemi R (5) Tosi A (6) Parodi A (7) Banelli B (8) Rigo V (9) Mastracci L (10) Grillo F (11) Cereghetti A (12) Tastanova A (13) Ghosh A (14) Sallustio F (15) Emionite L (16) Daga A (17) Altosole T (18) Filaci G (19) Rosato A (20) Levesque M (21) Maio M (22) Pfeffer U (23) Croce M
(1) Amaro A (2) Reggiani F (3) Fenoglio D (4) Gangemi R (5) Tosi A (6) Parodi A (7) Banelli B (8) Rigo V (9) Mastracci L (10) Grillo F (11) Cereghetti A (12) Tastanova A (13) Ghosh A (14) Sallustio F (15) Emionite L (16) Daga A (17) Altosole T (18) Filaci G (19) Rosato A (20) Levesque M (21) Maio M (22) Pfeffer U (23) Croce M
Author Info: (1) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (2) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy
Author Info: (1) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (2) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (3) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. Department of Internal Medicine, University of Genova, Genova, Italy. (4) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (5) Immunology and Molecular Oncology Diagnostics, Istituto Oncologico Veneto IRCCS, Padova, Italy. (6) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (7) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (8) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (9) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (10) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (11) Department of Dermatology, University of Zurich, University Hospital of Zurich, Zurich, Switzerland. (12) Department of Dermatology, University of Zurich, University Hospital of Zurich, Zurich, Switzerland. (13) Functional Genomics Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland. (14) Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy. (15) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (16) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (17) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. (18) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. Department of Internal Medicine, University of Genova, Genova, Italy. (19) Immunology and Molecular Oncology Diagnostics, Istituto Oncologico Veneto IRCCS, Padova, Italy. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. (20) Department of Dermatology, University of Zurich, University Hospital of Zurich, Zurich, Switzerland. (21) University of Siena, Siena, Italy. (22) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy. ulrich.pfeffer@hsanmartino.it. (23) IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genova, Italy.
Citation: J Exp Clin Cancer Res 2023 Mar 18 42:67 Epub03/18/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36934257
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment Featured
(1) Klement JD (2) Redd PS (3) Lu C (4) Merting AD (5) Poschel DB (6) Yang D (7) Savage NM (8) Zhou G (9) Munn DH (10) Fallon PG (11) Liu K
Investigating the role of PD-L1 on tumor cells, Klement and Redd et al. found that it did not affect primary tumor growth or directly limit CTL activity, but did engage with PD-1 on myeloid cells, activating SHP2 and inhibiting IFN-I signaling at sites of metastasis. When this mechanism was interrupted, IFN-I signaling increased, leading to increased STAT1, increased MHC-I and MHC-II expression, and increased production of CTL-recruiting chemokines, CXCL9 and CXCL10. This increased CTL recruitment, which helped to control and limit metastatic tumor outgrowth. In patient data, responses to PD-1 blockade correlated with IFN-I responses in myeloid cells.
(1) Klement JD (2) Redd PS (3) Lu C (4) Merting AD (5) Poschel DB (6) Yang D (7) Savage NM (8) Zhou G (9) Munn DH (10) Fallon PG (11) Liu K
Investigating the role of PD-L1 on tumor cells, Klement and Redd et al. found that it did not affect primary tumor growth or directly limit CTL activity, but did engage with PD-1 on myeloid cells, activating SHP2 and inhibiting IFN-I signaling at sites of metastasis. When this mechanism was interrupted, IFN-I signaling increased, leading to increased STAT1, increased MHC-I and MHC-II expression, and increased production of CTL-recruiting chemokines, CXCL9 and CXCL10. This increased CTL recruitment, which helped to control and limit metastatic tumor outgrowth. In patient data, responses to PD-1 blockade correlated with IFN-I responses in myeloid cells.
ABSTRACT: The cellular and molecular mechanisms underlying tumor cell PD-L1 (tPD-L1) function in tumor immune evasion are incompletely understood. We report here that tPD-L1 does not suppress cytotoxic T lymphocyte (CTL) activity in co-cultures of tumor cells and tumor-specific CTLs and exhibits no effect on primary tumor growth. However, deleting tPD-L1 decreases lung metastasis in a CTL-dependent manner in tumor-bearing mice. Depletion of myeloid cells or knocking out PD-1 in myeloid cells (mPD-1) impairs tPD-L1 promotion of tumor lung metastasis in mice. Single-cell RNA sequencing (scRNA-seq) reveals that tPD-L1 engages mPD-1 to activate SHP2 to antagonize the type I interferon (IFN-I) and STAT1 pathway to repress Cxcl9 and impair CTL recruitment to lung metastases. Human cancer patient response to PD-1 blockade immunotherapy correlates with IFN-I response in myeloid cells. Our findings determine that tPD-L1 engages mPD-1 to activate SHP2 to suppress the IFN-I-STAT1-CXCL9 pathway to impair CTL tumor recruitment in lung metastasis.
Author Info: (1) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical
Author Info: (1) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. (2) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. (3) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. (4) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. (5) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. (6) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. (7) Department of Pathology, Medical College of Georgia, Augusta, GA 30912, USA. (8) Georgia Cancer Center, Augusta, GA 30912, USA. (9) Georgia Cancer Center, Augusta, GA 30912, USA. (10) Trinity Biomedical Sciences Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland. (11) Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. Electronic address: kliu@augusta.edu.
Citation: Cancer Cell 2023 Mar 13 41:620-636.e9 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36917954
Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination
(1) Xu H (2) Zhao F (3) Wu D (4) Zhang Y (5) Bao X (6) Shi F (7) Cai Y (8) Dou J
(1) Xu H (2) Zhao F (3) Wu D (4) Zhang Y (5) Bao X (6) Shi F (7) Cai Y (8) Dou J
Author Info: (1) Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China; Department of Gynecology & Obstetrics, Zhongda Hospital, Schoo
Author Info: (1) Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China; Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. (2) Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China. (3) Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. (4) Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. (5) Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China. (6) Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. (7) Department of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. (8) Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China. Electronic address: njdoujun@seu.edu.cn.
Citation: Biomed Pharmacother 2023 Mar 16 161:114547 Epub03/16/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36933377
Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer
(1) Qin H (2) Hu H (3) Liao X (4) Zhao P (5) He W (6) Su X (7) Sun J (8) Li Q
(1) Qin H (2) Hu H (3) Liao X (4) Zhao P (5) He W (6) Su X (7) Sun J (8) Li Q
Author Info: (1) Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. (2) Breast Disease Center, The Affiliated Hos
Author Info: (1) Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. (2) Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, 266071, China. (3) Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. (4) Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. (5) Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. (6) School of Basic Medicine, Wenzhou Medical University, Wenzhou Tea Mountain Higher Education Park, Wenzhou, 325000, China. (7) Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China. jiaxing20022001@163.com. (8) Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. liqressh1962@163.com.
Citation: J Cancer Res Clin Oncol 2023 Mar 18 Epub03/18/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36933035
Blocking Dectin-1 prevents colorectal tumorigenesis by suppressing prostaglandin E2 production in myeloid-derived suppressor cells and enhancing IL-22 binding protein expression
(1) Tang C (2) Sun H (3) Kadoki M (4) Han W (5) Ye X (6) Makusheva Y (7) Deng J (8) Feng B (9) Qiu D (10) Tan Y (11) Wang X (12) Guo Z (13) Huang C (14) Peng S (15) Chen M (16) Adachi Y (17) Ohno N (18) Trombetta S (19) Iwakura Y
(1) Tang C (2) Sun H (3) Kadoki M (4) Han W (5) Ye X (6) Makusheva Y (7) Deng J (8) Feng B (9) Qiu D (10) Tan Y (11) Wang X (12) Guo Z (13) Huang C (14) Peng S (15) Chen M (16) Adachi Y (17) Ohno N (18) Trombetta S (19) Iwakura Y
Author Info: (1) Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. tan
Author Info: (1) Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. tangc7@mail.sysu.edu.cn. Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. tangc7@mail.sysu.edu.cn. Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. tangc7@mail.sysu.edu.cn. (2) Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. (3) Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. (4) Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. (5) Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. (6) Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. (7) Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (8) Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (9) Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (10) Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (11) Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (12) Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (13) Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (14) Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (15) Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhong Shan Er Lu, 510080, Guangzhou, Guangdong Province, China. (16) Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, 192-0392, Japan. (17) Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, 192-0392, Japan. (18) Boehringer Ingelheim USA, 900 Ridgebury Rd, Ridgefield, CT, 06877, USA. (19) Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Yamazaki 2669, Noda-shi, Chiba, 278-0022, Japan. iwakura@rs.tus.ac.jp.
Citation: Nat Commun 2023 Mar 17 14:1493 Epub03/17/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36932082
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
(1) Jang HJ (2) Hostetter G (3) MacFarlane AW (4) Madaj Z (5) Ross EA (6) Hinoue T (7) Kulchycki JR (8) Burgos RS (9) Tafseer M (10) Alpaugh RK (11) Schwebel CL (12) Kokate R (13) Geynisman DM (14) Zibelman MR (15) Ghatalia P (16) Nichols PW (17) Chung W (18) Madzo J (19) Hahn NM (20) Quinn DI (21) Issa JJ (22) Topper MJ (23) Baylin SB (24) Shen H (25) Campbell KS (26) Jones PA (27) Plimack ER
(1) Jang HJ (2) Hostetter G (3) MacFarlane AW (4) Madaj Z (5) Ross EA (6) Hinoue T (7) Kulchycki JR (8) Burgos RS (9) Tafseer M (10) Alpaugh RK (11) Schwebel CL (12) Kokate R (13) Geynisman DM (14) Zibelman MR (15) Ghatalia P (16) Nichols PW (17) Chung W (18) Madzo J (19) Hahn NM (20) Quinn DI (21) Issa JJ (22) Topper MJ (23) Baylin SB (24) Shen H (25) Campbell KS (26) Jones PA (27) Plimack ER
Author Info: (1) Van Andel Institute, Grand Rapids, MI, United States. (2) Van Andel Institute, Grand Rapids, MI, United States. (3) Fox Chase Cancer Center, Philadelphia, PA, United States. (4
Author Info: (1) Van Andel Institute, Grand Rapids, MI, United States. (2) Van Andel Institute, Grand Rapids, MI, United States. (3) Fox Chase Cancer Center, Philadelphia, PA, United States. (4) Van Andel Institute, Grand Rapids, MI, United States. (5) Fox Chase Cancer Center, Philadelphia, PA, United States. (6) Van Andel Institute, Grand Rapids, United States. (7) Van Andel Institute, Grand Rapids, MI, United States. (8) Van Andel Institute, Grand Rapids, MI, United States. (9) Fox Chase Cancer Center, Philadelphia, PA, United States. (10) Fox Chase Cancer Center, Philadelphia, PA, United States. (11) Fox Chase Cancer Center, Philadelphia, PA, United States. (12) Fox Chase Cancer Center, Philadelphia, United States. (13) Fox Chase Cancer Center, Philadelphia, PA, United States. (14) Fox Chase Cancer Center, Philadelphia, PA, United States. (15) Fox Chase Cancer Center, Birmingham, AL, United States. (16) University of Southern California, Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA, United States. (17) Coriell Institute For Medical Research, Camden, NJ, United States. (18) Coriell Institute For Medical Research, Camden, NJ, United States. (19) Johns Hopkins School of Medicine, Baltimore, Maryland, United States. (20) University of Southern California, Los Angeles, CA, United States. (21) Coriell Institute For Medical Research, Camden, NJ, United States. (22) Johns Hopkins University, Baltimore, MD, United States. (23) Johns Hopkins University School of Medicine, Baltimore, MD, United States. (24) Van Andel Institute, Los Angeles, United States. (25) Fox Chase Cancer Center, Philadelphia, PA, United States. (26) Van Andel Institute, Grand Rapids, MI, United States. (27) Fox Chase Cancer Center, Philadelphia, PA, United States.
Citation: Clin Cancer Res 2023 Mar 16 Epub03/16/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36928921
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer
(1) Semeniuk-Wojta_ A (2) Podd_bniak-Strama K (3) Modzelewska M (4) Bary_a M (5) Dzi_g-Dudek E (6) Syry_o T (7) Grnicka B (8) Jakie_a A (9) Stec R
(1) Semeniuk-Wojta_ A (2) Podd_bniak-Strama K (3) Modzelewska M (4) Bary_a M (5) Dzi_g-Dudek E (6) Syry_o T (7) Grnicka B (8) Jakie_a A (9) Stec R
Author Info: (1) Oncology Department, Medical University of Warsaw, Warsaw, Poland. asemeniukwojtas@gmail.com. (2) Oncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw,
Author Info: (1) Oncology Department, Medical University of Warsaw, Warsaw, Poland. asemeniukwojtas@gmail.com. (2) Oncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw, Poland. (3) Pathomorphology Department, Medical University of Warsaw, Warsaw, Poland. (4) Oncology Department, Medical University of Warsaw, Warsaw, Poland. (5) Oncology Department, Medical University of Warsaw, Warsaw, Poland. (6) Department of General, Active and Oncological Urology, Military Institute of Medicine, Warsaw, Poland. (7) Pathomorphology Department, Medical University of Warsaw, Warsaw, Poland. (8) Oncology Department, 4 Military Clinical Hospital with a Polyclinic, Wroclaw, Poland. (9) Oncology Department, Medical University of Warsaw, Warsaw, Poland.
Citation: Cancer Immunol Immunother 2023 Mar 16 Epub03/16/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36928373
Regular Voluntary Running is Associated with Increased Tumor Vascularization and Immune Cell Infiltration and Decreased Tumor Growth in Mice
(1) Esteves M (2) Silva C (3) Bovolini A (4) Pereira SS (5) Morais T (6) Moreira å (7) Costa MM (8) Monteiro MP (9) Duarte JA
(1) Esteves M (2) Silva C (3) Bovolini A (4) Pereira SS (5) Morais T (6) Moreira å (7) Costa MM (8) Monteiro MP (9) Duarte JA
Author Info: (1) Instituto de Investigao, Inovao e Desenvolvimento Fernando Pessoa (FP-I3ID), Escola Superior de Saude Fernando Pessoa, Porto, Portugal. Laboratory of Biochemistry and Exper
Author Info: (1) Instituto de Investigao, Inovao e Desenvolvimento Fernando Pessoa (FP-I3ID), Escola Superior de Saude Fernando Pessoa, Porto, Portugal. Laboratory of Biochemistry and Experimental Morphology, CIAFEL, Porto, Portugal. (2) Laboratory of Biochemistry and Experimental Morphology, CIAFEL, Porto, Portugal. (3) Laboratory of Biochemistry and Experimental Morphology, CIAFEL, Porto, Portugal. (4) Clinical and Experimental Endocrinology, Unit for Multidisciplinary Research in Biomedicine, University of Porto Institute of Biomedical Sciences Abel Salazar, Porto, Portugal. (5) Clinical and Experimental Endocrinology, Unit for Multidisciplinary Research in Biomedicine, University of Porto Institute of Biomedical Sciences Abel Salazar, Porto, Portugal. (6) Communication Unit, Universidade do Porto Instituto de Investigao e Inovao em Sade, Porto, Portugal. (7) Clinical and Experimental Endocrinology, Unit for Multidisciplinary Research in Biomedicine, University of Porto Institute of Biomedical Sciences Abel Salazar, Porto, Portugal. (8) Clinical and Experimental Endocrinology, Unit for Multidisciplinary Research in Biomedicine, University of Porto Institute of Biomedical Sciences Abel Salazar, Porto, Portugal. (9) Laboratory of Biochemistry and Experimental Morphology, CIAFEL, Porto, Portugal. TOXRUN, University Institute of Health Sciences, CESPU, Gandra, Portuga.
Citation: Int J Sports Med 2023 Mar 17 Epub03/17/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36931293
Tags:
Complexity and diversity of FOXP3 isoforms: Novel insights into the regulation of the immune response in metastatic breast cancer
(1) Malla R (2) Adem M (3) Chakraborty A
(1) Malla R (2) Adem M (3) Chakraborty A
Author Info: (1) Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam 530045, Andhra Pradesh, India.
Author Info: (1) Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam 530045, Andhra Pradesh, India. Electronic address: rmalla@gitam.edu. (2) Department of Biotechnology, Sri Padmavathi Mahila Visvavidhyalayam, Tirupati 517502, Andhra Pradesh, India. (3) Radiation Biology Laboratory, UGC-DAE-CSR, Kolkata Centere, Kolkata 700098, West Bengal, India.
Citation: Int Immunopharmacol 2023 Mar 15 118:110015 Epub03/15/2023
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36931171